News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Drug interactions and pharmacokinetics
Once daily Kaletra: dose escalation rarely the answer for those with low plasma levels

Even after dose escalation, plasma concentrations of once-daily Kaletra (lopinavir/ritonavir) rarely reach therapeutic levels in some patients, according to a study published in the July

Published
21 June 2005
By
Michael Carter
Side-effects
Duration of ddI treatment and dose risk factors for CD4 loss in patients taking ddI/tenofovir

Duration of ddI (Videx) therapy and ddI dose are risk factors for the loss of CD4 T-cells in patients with a controlled viral load taking

Published
21 June 2005
By
Michael Carter
Drug interactions and pharmacokinetics
Tenofovir may linger up to 3 weeks in body: discontinue with caution

Sub-optimal levels of tenofovir (Viread) that could lead to drug resistance may linger in the body for at least three weeks after the drug is

Published
14 June 2005
By
Keith Alcorn
Drug interactions and pharmacokinetics
Efavirenz and anti-convulsant drug phenytoin interact: TDM of value when used together

An interaction between efavirenz (Sustiva) and the anti-convulsant drug, phenytoin (Epanutin), resulted in suboptimal blood levels of efavirenz and increased concentrations of phenytoin, according to

Published
08 June 2005
By
Michael Carter
Contraception
Increased risk of oral contraceptive failure with nelfinavir

HIV-positive women taking oral contraceptives and the protease inhibitor nelfinavir are significantly more likely to experience contraceptive failure and become pregnant, according to a retrospective

Published
07 September 2004
By
Michael Carter
Drug interactions and pharmacokinetics
What to do with nelfinavir?

Two studies presented on Monday at the 40th ICAAC raised some difficult questions about the role of nelfinavir in antiretroviral therapy. Nelfinavir is one of

Published
05 March 2001
By
Keith Alcorn
Chemsex and recreational drug use
Potential fatal interaction between protease inhibitors and crystal meth

Australian doctors have reported what they believe to be a fatal interaction between ritonavir and methamphetamine, commonly known as crystal or crystal meth. Crystal is

Published
05 March 2001
By
Keith Alcorn
← Prev1...2021222324Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.